about
A cotwin-control analysis of drug use and abuse/dependence risk associated with early-onset cannabis useAn observational study of musculoskeletal pain among patients receiving bisphosphonate therapyGenetic vulnerability and phenotypic expression of depression and risk for ischemic heart disease in the Vietnam era twin study of aging.Effect of paternal alcohol and drug dependence on offspring conduct disorder: gene-environment interplayContribution of parental psychopathology to offspring smoking and nicotine dependence in a genetically informative design.Change in opioid dose and change in depression in a longitudinal primary care patient cohort.Increased risk of myocardial infarction in depressed patients with type 2 diabetes.Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?Assessment of a postdeployment Yellow Ribbon Reintegration Program for National Guard members and supportersA test for common genetic and environmental vulnerability to depression and diabetes.Will electronic health record data become the standard resource for clinical research?Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations.Shared genetic contributions to anxiety disorders and pathological gambling in a male population.Increased Risk of Depression Recurrence After Initiation of Prescription Opioids in Noncancer Pain Patients.New depression diagnosis following prescription of codeine, hydrocodone or oxycodone.Prescription opioid analgesics increase the risk of depressionEnvironmental factors selectively impact co-occurrence of problem/pathological gambling with specific drug-use disorders in male twins.Myocardial infarction risk among patients with fractures receiving bisphosphonatesInsurance coverage and diabetes quality indicators among patients with diabetes in the US general population.Higher Referrals for Diabetes Education in a Medical Home Model of Care.Rate of renal function decline, race and referral to nephrology in a large cohort of primary care patients.Self-Reported Lifetime Depression and Current Mental Distress Among Veterans Across Service Eras.New-onset depression following stable, slow, and rapid rate of prescription opioid dose escalation.The influence of prescription opioid use duration and dose on development of treatment resistant depression.Patient Portal Use and Blood Pressure Control in Newly Diagnosed Hypertension.Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression.Racial differences in the association between nonmedical prescription opioid use, abuse/dependence, and major depression.Exposure to paternal alcoholism does not predict development of alcohol-use disorders in offspring: evidence from an offspring-of-twins study.Comparison of Medical Diagnoses among Same-Sex and Opposite-Sex-Partnered Patients.Shared genetic contributions to pathological gambling and major depression in men.Are substance use, abuse and dependence associated with study participation? Predictors of offspring nonparticipation in a twin-family study.Use of an Online Patient Portal and Glucose Control in Primary Care Patients with Diabetes.Comparison of Adherence to Guideline-Based Cholesterol Treatment Goals in Men Versus Women.Race and referral to diabetes education in primary care patients with prediabetes and diabetes.Depression leads to incident vascular disease: evidence for the relevance to primary care.Internal medicine resident training and provision of diabetes quality of care indicators.Cholesterol treatment and changes in guidelines in an academic medical practice.Differences in prescribing patterns for anxiety and depression between General Internal Medicine and Family Medicine.Models of treatment seeking for alcoholism: the role of genes and environment.SMART designs in observational studies.
P50
Q33562500-FD1AFBC9-A680-4F6F-8101-707E426806B9Q33765055-E7C80A3B-870B-4653-B256-CA65C0972212Q33869891-09792B34-08C7-433B-BD45-5BDC6F22CD60Q34091540-81E5F120-A757-408A-B023-22BF1FF71AD3Q34093419-7FBAD9B1-0718-4AAE-870E-F0ECCE65E150Q34988126-968BD543-7261-4687-8B1D-24A3790B981AQ35123387-8ECD72BA-4D93-4996-A5E5-245FA86D3B5FQ35562732-E8753E62-9862-41DE-B954-8EB7AC27AF5BQ35585784-F135F562-CC7E-460B-B71B-6DAB880119E0Q36344452-F72082CE-A637-40DA-8D03-BAE7D3CA0051Q36410572-2D28879E-91C1-4618-A22A-D151B1EE7994Q36452126-96ED9277-08F0-4260-8B44-9439023CF959Q36898952-0699856C-4471-4705-8226-D4E4C4C260E3Q36961590-BD5517DD-42C0-41A8-AE06-BE841FD728FDQ36996381-6A9B75C4-C2DE-49A3-875F-B642355E64AEQ37595812-A2A755CA-39F5-4AE3-BECF-40FFD9ACE7EAQ37633541-A0CBE8B3-EDC9-40A4-9AD7-3AFD1B7893D3Q37673078-3A9F8271-E799-4FCD-BA76-D38262716BDBQ38723661-B650F164-ADC3-4FD4-8C73-B7764C24FE0AQ38868165-0A5CE89E-D5AF-4B3A-8B32-6DE14BF690CAQ38882301-C2BAF38C-80D6-4DB4-AA01-90405C843EA3Q38909478-919C3D95-B38A-425C-88E3-230CDAF837B8Q39018188-99CC493C-7191-412A-A590-83E86E0C14A9Q39516963-7EDE55E2-73C4-4F8B-A910-7A3B54DC30FAQ39622409-E0C81962-0A17-4249-8DDE-2774E6CE72E9Q40130770-A6231351-81DD-438F-8525-B0C262F16D4DQ40203539-B250579C-5EB8-436C-945D-F08DEC32DB12Q40306355-59D3C918-9966-4450-9ED1-B5337F55CF34Q40376695-B1CB8F62-22DC-4DAD-BC86-2AD5A7D814A2Q40391328-A66ED33E-1071-4B69-B592-8541CB3BD37FQ40527403-743EE2C6-C637-42EA-84FD-1786FB97BA33Q40666147-E90DEEFC-1E17-4545-89B2-D9B5248E9D89Q41109103-3FF501C8-16F7-4151-9038-4F0AAA97AFE8Q41337223-9A2E8C19-98B6-41EF-A269-F0BF265B3007Q41456565-64C17B9C-1580-47EE-B422-BB2A3A69C10AQ41700344-8B8036F2-3F19-4E7C-B121-D25FC67A8314Q41742730-47AB7E30-C60A-41C8-82C4-57616E0D857CQ41753514-C5221166-9E85-428F-AF12-E07C0A6A5746Q42647648-3523E4BE-6A95-4E90-B378-F23143C2C15AQ42700652-FEB6C48A-EFFE-4E74-BBF4-3C973D8F47E9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jeffrey F Scherrer
@ast
Jeffrey F Scherrer
@en
Jeffrey F Scherrer
@es
Jeffrey F Scherrer
@nl
type
label
Jeffrey F Scherrer
@ast
Jeffrey F Scherrer
@en
Jeffrey F Scherrer
@es
Jeffrey F Scherrer
@nl
prefLabel
Jeffrey F Scherrer
@ast
Jeffrey F Scherrer
@en
Jeffrey F Scherrer
@es
Jeffrey F Scherrer
@nl
P106
P1153
7103110775
P31
P496
0000-0002-9148-2863